BioSpace News Archive

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022.

Animol Discovery, Inc., a pioneer in veterinary pharmaceutical discovery, announced it has raised $34.0 million in Series B financing.

Biogen Inc. (Nasdaq: BIIB) today announced that TheNew England Journal of Medicine (NEJM) has published positive results from the cutaneous lupus erythematosus (CLE) portion of the two-part Phase 2 LILAC study (Part B) evaluating litifilimab (known as BIIB059), an investigational drug for the treatment of lupus.

This addition to Biomica’s scientific expertise will support the company’s upcoming steps in its immuno-oncology clinical development program.

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 , before the opening of the U.S. financial markets.

Better Therapeutics, Inc today announced the completion of the pivotal clinical trial for BT-001, an investigational first-in-class prescription digital therapeutic that is designed to use nCBT to treat type 2 diabetes (T2D).

Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report second quarter 2022 financial results before the market opens on Thursday, August 11, 2022.

Selecta Biosciences, Inc. today announced that it plans to host a conference call on Thursday, August 4, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a business update.

Caladrius Biosciences, Inc. today announced that the Company will report its financial results for the three and six months ended June 30, 2022, on Thursday, August 4, 2022, at 4:30 p.m. (EDT).